Background: Advances in cancer genome sequencing have led to the development of various next-generation sequencing (NGS) platforms. There is paucity of data regarding concordance of different NGS tests carried out in the same patient.
Introduction
Advances in cancer genome sequencing aim to help clinicians with prevention, early detection, diagnosis, and treatment decisions. Well-known examples include BRCA1/2, EGFR, HER2, KRAS, ALK, ROS, and BRAF alterations, among others [1] [2] [3] . Urothelial cancer is an excellent model for studying tumor biology, genomic features, and the role of gene-environment interaction in cancer progression via serial sampling; moreover, it is among the tumors with the highest frequency of germline and somatic mutations [4] [5] [6] . A variety of next-generation sequencing (NGS) platforms analyzing tumor tissue and more recently, cell-free circulating tumor (ct) DNA are available for clinical testing of genomic alterations (GA) [7] [8] [9] [10] . A few studies have looked at the concordance between different NGS platforms. Recently, Kuderer et al. [7] showed significant discordance between these same NGS panels in a limited number of patients with diverse solid tumors. To this end, very little is known about the concordance of NGS platforms using different specimens (tissue, ctDNA) from the same patient with metastatic bladder/urothelial cancer.
Methods
The Institutional Review Board of the Cleveland Clinic Foundation approved this retrospective study. All patients were seen in the Taussig Cancer Center, Cleveland Clinic. Twenty-two patients with metastatic bladder cancer with available NGS data from both archival tumor tissue (FoundationOne) and ctDNA (Guardant360) were analyzed. The FoundationOne (F1; Foundation Medicine) test used formalin-fixed, paraffin-embedded (FFPE) tumors to sequence exons from 315 cancerassociated genes and introns from 28 genes involved in rearrangements [8] . The Guardant360 (G360, Guardant Health) test used ctDNA from blood to sequence 73 different genes [9] . As the G360 platform recently updated the number of alterations tested (from 68 to a total of 73 genes, as for now), the authors discussed with GuardantHealth team about which GA could be identified by G360 test to assess accurate concordance. Synonymous (silent) mutations were excluded from both tests.
We compared reports from F1 and G360 tests and listed all known GA as well as variants of unknown significance (VUS) detected by F1. Potential ongoing clinical trials suggested in F1 and G360 reports were presented. Tumor mutational burden (TMB) and microsatellite stability data were reported in F1 reports. To assess concordance between tests, the number of mutually tested GA divided by the number of total GA (present in either test) for each patient was assessed; median/range of concordance in all patients was calculated (only GA detectable by both platforms were considered). For calculation of concordance between F1 and G360, the first G360 test was the closest to the time of tissue collection in the five patients with serial ctDNA testing. The cases with no GA found in G360 (patient 13, 18) were excluded for the calculation of concordance rates.
The concordance of recommended systemic therapies was the result of the number of genes (with GA noted in both assays) with at least one suggested therapy, divided by the total number of genes with suggested therapies in either report. Descriptive statistics were used; paired samples t-tests were used to compare the mean number of known GA in the two platforms; and linear regression was used to compare tumor tissue mutational burden and the number of known GA, number of VUS, and the number of total GA [both known (non-VUS) and VUS]; P < 0.05 was considered significant.
Results
Clinical characteristics of patients and tumors are summarized in Table 1 . Twenty-two patients (16 men and 6 women), 20 with predominant urothelial carcinoma, a man with small-cell carcinoma of bladder and a woman with adenocarcinoma of bladder, median age 74 (range 49-82), were included in this analysis. Tumor samples (FFPE) from primary (n ¼ 16) or recurrent (n ¼ 6) disease were used. Median time difference between archival tumor acquisition and ctDNA collection for NGS testing was 8.0 (0-32.8) months. All G360 tests were ordered in the advanced disease setting. Archival tissue used for F1 was collected before the diagnosis of metastatic disease in 59% (n ¼ 13) of the cases, and blood was collected either around the same time or after the diagnosis of metastatic disease, for each patient. In 6 cases (pt. 2, 10, 12, 13, 16, 22), tumor tissue for F1 and blood for G360 were collected with a median difference of 35.5 (0-71) days between the two. Median time between the diagnosis of stage IV and the first genomic test was 23.5 days (0-767) after a median number of 0 (0-3) prior systemic lines of treatment of advanced disease (Table 2) . Most frequent GA found (no. ctDNA/tissue; total %) in this cohort involved the genes TP53 (10/12; 50.0%), TERT promoter (14/2; 36.3%); ARID1 (5/8; 29.5%); FGFR2/3 (4/5; 20.5%), PIK3CA (5/4; 20.5%), and ERBB2 (2/6; 18.2%). Specific GA found in each NGS test are summarized in supplementary Table  S1 , available at Annals of Oncology online. There was no significant difference between the frequency of those GA noted here and the frequency of those GA reported in the TCGA study (P ¼ 0.078), which was based on tumor tissue.
Tumors had a median of 12 (4-57) VUS in F1 reports. There was numerical but no statistically significant difference between the number of known GA [8.82 in G360 versus 3.10 in F1; P ¼ 0.209 (paired samples correlation test)]. The average concordance between paired tests among all patients was 16.4% (0%-50%). In the six patients (pt. 2, 10, 12, 13, 16, 22) with F1 and G360 collected around the same time, average concordance was 17.1% (0%-50%). Notably, 5 patients (pt. 1, 12, 14, 16, 22) had 2 ctDNA tests: the second test was carried out after a median of 7.4 (2.6-10.0) months and 1 (1-2) systemic therapy. The most common GA in those five patients were detected in the genes TP53 (100.0%), NOTCH1 (60.0%), ERBB2 (60.0%) and BRAF (50.0%), and the average concordance between the two ctDNA tests was 55.5% (12.1%-100.0%).
There was a median of two and one systemic therapies suggested in F1 and G360 reports. Concordance of recommended systemic therapies was 14%, 65.9%, and 57.0% systemic therapies were recommended by F1 and G360 reports, respectively. Table 3 summarizes the ongoing clinical trials with agents targeting the most frequent (15%) known GA found in F1 and G360 tests. All genes with GA, except for TERT promoter and ARID1, had multiple suggested relevant clinical trials. Most tumors (81.8%) were microsatellite stable, and the median tumor tissue mutational burden was 8 mutations/Mb. Tumor tissue mutational burden was associated with the number of known GA in F1 report (P ¼ 0.009), number of VUS in F1 report (P < 0.001), total number of GA (VUS and non-VUS) in F1 report (P < 0.001), and number of GA in G360 report (P < 0.001). The number of VUS in F1 report also correlated with the number of GA in G360 (P ¼ 0.012) and number of total GA (VUS and non-VUS) (P < 0.001) in F1 report.
Discussion
Recent genome-wide expression and sequencing studies have helped identify unique molecular features serving as key drivers in muscle-invasive bladder cancer [11, 12] . A comprehensive analysis of 131 high-grade, muscle-invasive urothelial bladder carcinomas as part of the TCGA project identified significant recurrent alterations in 32 different genes with a frequency of 4%-49%; however, updated data were presented at the 2017 Annual ASCO Meeting and will be published soon [11] . Not surprisingly, GA identified in our study represent genes involved in cell-cycle regulation, proliferation, growth, survival, signaling, DNA repair, chromatin remodeling among other pathways, and are similar to those reported in TCGA and other tissue-based NGS studies [11] [12] [13] [14] [15] . In line with the TCGA analysis, ERBB2 was the only frequent gene (>15%) found in our cohort with detected in <10% of the TCGA cases. Of note, the second most common alteration was identified in the promoter region of TERT gene (36%), which is a non-exomic region not sequenced by TCGA [11, 16] . There remains an urgent need for new treatments in advanced urothelial cancer, since most patient progress on front-line chemotherapy and until the recent approval of five immune checkpoint inhibitors, there was no standard of care for second line therapy of advanced disease [17] [18] [19] [20] [21] [22] [23] . To our knowledge, this is one of the first studies performing intra-individual comparisons of different NGS platforms with paired tumor tissue and ctDNA, and the first analysis including only patients with advanced urothelial/bladder cancer [7, [24] [25] [26] . Our results support the need for further assessment of the clinical utility of NGS testing in informing treatment decisions for these patients, especially in the current era with multiple targeted agents in development and a need for patient selection, as shown in Table 3 . Nevertheless, despite the high number of GA detected, not all of them are targetable (TP53 is a good example); and when they are, NGS-based treatment-in the context of precision oncologyneeds further evaluation in different trials, such as NCI-MATCH (NCT02465060), MY Pathway (NCT02091141), BISCAY (NCT02546661), among others [27] [28] [29] .
Although our numbers are small, the median number of systemic therapies suggested by F1 and G360 and the low number (0.41) of concordant genes with suggested therapies in both F1 and G360 could indicate that these tests may have 'additive' value. Even if tumor tissue might have more abundant DNA, genomic material from a single site may not represent the overall tumor burden and heterogeneity across different body sites. As hypothesis generating for future research, it is plausible that these tests might serve complementary (and not interchangeable) functions-possibly one for increased 'single-site sensitivity', and the other for increased 'across-sites sensitivity'; providing further information of the 'ever evolving' tumor biology.
In this study, we also evaluated the number of VUS (F1 report) to capture more broadly the genomic landscape of these tumors, and we noted a significant correlation between the number of reported VUS and the mutational burden of tumors. Similarly, mutational burden of tumor tissue correlated highly with the total number of GA (known and VUS) in F1 reports, raising the question whether the total number of GA in ctDNA may be a surrogate marker for mutational burden, which was also noted in our cohort. This is a clinically relevant question since tumor tissue mutational burden was a potent predictor of response to atezolizumab (anti-PDL1 immune checkpoint inhibitor) in the phase II IMvigor210 trial that led to its FDA approval in platinumrefractory advanced urothelial cancer [18, 19] . The used ctDNA platform in our study evaluated up to 73 genes, which limits the ability to comprehensively assess TMB. If TMB in urothelial cancer correlates with total detectable ctDNA mutational allele burden and the number of GA in ctDNA, then circulatory surrogate biomarkers may be further evaluated; specific gene mutation allele fraction is also important [5, 30] .
As recognized in prior studies the type/origin of cancer, different timing of bio-specimen collection, and site/location of analyzed tissue are important factors affecting the degree of concordance between these two NGS platforms. In our cohort, the majority of analyzed tissues were from the archival primary tumor. While most patients (n ¼ 13) had archival tissue available before any systemic treatment was used for advanced disease, ctDNA was collected with a median of less than a month from diagnosis of advanced disease, after a median of 8 months after archival tissue collection. Tumor progression and interim therapies may have allowed clonal evolution and further tumor heterogeneity that may have affected NGS testing concordance [31, 32] . The potential effect of these variables on testing concordance was shown in a recent study using whole-exome sequencing and clonality assessment in urothelial cancer samples before and after chemotherapy that demonstrated intra-patient mutational heterogeneity and discordant mutations among different tumor sites [31] . Moreover, chemotherapy may induce mutagenesis that can further affect tumor evolution over time. Nevertheless, in the six patients with both tissue and ctDNA collected around the same time, testing concordance was still low, further suggesting that these tests might be complementary. The optimal cut-point of ctDNA mutation allele detection and level of gene amplification are additional factors that may affect the concordance and the biological relevance of the results; further refinement and harmonization is needed. Importantly, different studies have detected circulating tumor cells (CTC) in <50% in patients with advanced urothelial cancer and CTC have not yet shown clinical utility in this disease [33, 34] . The higher concordance rates noted in different neoplasms, such as lung and breast cancer, support the concept that specific tumor type is a decisive factor impacting the degree of concordance between tissue and ctDNA-based platforms [35, 36] . It is also worth emphasizing that the concordance of altered genes between tests (20.0%) was only modestly higher than the concordance for specific GA (16.4%).
Insight into tumor biology via NGS can be utilized at baseline (pre-treatment) to identify putative therapeutic targets and potential prognostic/predictive biomarkers; it may also have the potential to be used serially to assess response, mechanisms of resistance to therapy, and clonal evolution. Prospective clinical trial designs are being explored to approach those questions, and discussions are ongoing in the co-operative research group setting on these topics to further assess applications of clinical utility.
Although preliminary and in a small number of patients, our findings suggest a significant discordance between clinically available NGS panels in urothelial cancer, even when collected around the same time. Tumor type, timing of specimen collection, intratumoral heterogeneity, clonal evolution, discrete gene alteration types and assays, also with different gene content, partially explain the discordance. However, we observed high concordance between serial ctDNA tests in the longitudinal evaluation of five patients despite interim systemic treatments. The results also suggest that serial sampling may reveal 'truncal' and 'branching' GA in the course of the disease [37] .
So far, tumor tissue NGS has been the most commonly used method to inform clinical decision making. Besides being easier, more feasible, less labor-intensive, and less invasive, ctDNA has the potential to be used to monitor response/resistance and predict outcomes, as shown in a recent study in patients treated with immune checkpoint inhibitors [38] . The data supporting the use of ctDNA are promising, and the impact of using that approach on outcomes should be tested in additional clinical trials, along with tumor tissue testing. As different NGS platforms are increasingly being used, prospective studies and larger cohorts may help better understand and integrate their results into clinical practice, and also further define the so dynamic tumor biology.
